Last reviewed · How we verify
IRL790
At a glance
| Generic name | IRL790 |
|---|---|
| Sponsor | Integrative Research Laboratories AB |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Mesdopetam in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia (PHASE2)
- Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia (PHASE2)
- A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IRL790 CI brief — competitive landscape report
- IRL790 updates RSS · CI watch RSS
- Integrative Research Laboratories AB portfolio CI